Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients

Creative Commons License

Yiğenoğlu T. N. , Başcı S., Şahin D., Ulaş T., Dal M. S. , Korkmaz S., ...More

Transfusion and Apheresis Science, 2021 (Journal Indexed in SCI Expanded) identifier identifier

  • Publication Type: Article / Review
  • Publication Date: 2021
  • Doi Number: 10.1016/j.transci.2021.103237
  • Title of Journal : Transfusion and Apheresis Science
  • Keywords: COVID-19, Mesenchymal stem cell, SARS-CoV-2, Transfusion, Transplantation


© 2021 Elsevier LtdSARS-CoV-2 attaches to the angiotensin-converting enzyme 2 (ACE-2) receptor on human cells. The virus causes hypercytokinemia, capillary leak, pulmonary edema, acute respiratory distress syndrome, acute cardiac injury, and leads to death. Mesenchymal stem cells (MSCs) are ACE-2 negative cells; therefore, can escape from SARS-CoV-2. MSCs prevent hypercytokinemia and help the resolution of the pulmonary edema and other damages occurred during the course of COVID-19. In addition, MSCs enhance the regeneration of the lung and other tissues affected by SARS-CoV-2. The case series reported beneficial effect of MSCs in COVID-19 treatment. However, there are some concerns about the safety of MSCs, particularly referring to the increased risk of disseminated intravascular coagulation, and thromboembolism due to the expression of TF/CD142. Prospective, randomized, large scale studies are needed to reveal the optimum dose, administration way, time, efficacy, and safety of MSCs in the COVID-19 treatment.